General Anaesthetic Drugs do More than Just Induce Sleep
A new understanding of the complex ways in which general anaesthetics act on the brain could eventually lead to improved drugs for surgery. The research is published in Cell Reports.
University of Queensland researcher, Associate Professor Bruno van Swinderen said his team had overturned previous understanding of what general anaesthetics did to the brain, finding the drugs did much more than induce sleep.
"We looked at the effects of propofol – one of the most common general anaesthetic drugs used during surgery - on synaptic release," the UQ Queensland Brain Institute scientist said.
Synaptic release is the mechanism by which neurons – or nerve cells – communicate with each other.
"We know from previous research that general anaesthetics including propofol act on sleep systems in the brain, much like a sleeping pill," Associate Professor van Swinderen said.
"But our study found that propofol also disrupts presynaptic mechanisms, probably affecting communication between neurons across the entire brain in a systematic way that differs from just being asleep.
“In this way it is very different than a sleeping pill."
PhD student Adekunle Bademosi said the discovery shed new light on how general anaesthetics worked on the brain.
"We found that propofol restricts the movement of a key protein (syntaxin1A) required at the synapses of all neurons," he said.
“This restriction leads to decreased communication between neurons in the brain."
Associate Professor van Swinderen said the finding contributed to understanding how general anaesthetics worked, and could explain why people experienced grogginess and disorientation after coming out of surgery.
"We think that widespread disruption to synaptic connectivity – the brain's communication pathways – is what makes surgery possible, although effective anaesthetics such as propofol do put you to sleep first," he said.
"The discovery has implications for people whose brain connectivity is vulnerable, for example in children whose brains are still developing or for people with Alzheimer's or Parkinson's disease.
"It has never been understood why general anaesthesia is sometimes problematic for the very young and the old. This newly discovered mechanism may be a reason."
Associate Professor van Swinderen said more research was needed to determine if general anaesthetics had any lasting effects in these vulnerable groups of people.
"Studying these effects in model systems such as rats and flies allows us to address these questions by manipulating the likely mechanisms involved, which we can't do in humans."
The research involved Professor Frederic Meunier's laboratory at QBI, where super-resolution microscopy techniques enabled the researchers to understand how the anaesthetic worked on single cells. Dr Victor Anggono, whose laboratory at QBI focusses on synaptic mechanisms, was a partner in the study.
This article has been republished from materials provided by University of Queensland. Note: material may have been edited for length and content. For further information, please contact the cited source.
Bademosi, A. T., Steeves, J., Karunanithi, S., Zalucki, O. H., Gormal, R. S., Liu, S., . . . Swinderen, B. V. (2018). Trapping of Syntaxin1a in Presynaptic Nanoclusters by a Clinically Relevant General Anesthetic. Cell Reports, 22(2), 427-440. doi:10.1016/j.celrep.2017.12.054
Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous SclerosisNews
Addressing a critical issue for people with a genetic disorder called tuberous sclerosis complex (TSC), doctors reported that a skin cream containing rapamycin significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with the condition.READ MORE
Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug DevelopmentNews
Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE